Dynamic cross-flow electro-Fenton process coupled to anodic oxidation for wastewater treatment: application to the degradation of acetaminophen

In this work, we present an integrated dynamic cross-flow electro-Fenton (DCF-EF) system for the treatment of the pharmaceutical, acetaminophen (paracetamol), in aqueous medium. A carbonaceous electrocatalytic membrane was used as cathode, allowing the continuous production of H2O2 during EF in dynamic filtration mode. The transmembrane pressure (TMP) and current were the two driving forces of the system, whose influence strongly affected the global efficiency. It was found that H2O2 production from the electrochemical reduction of dissolved O2 was favoured at higher TMP values as a consequence of an increase of the O2 partial pressure, and higher H2O2 amounts entailed an increase in the efficiency of the process. Current also had a positive effect on H2O2 production and acetaminophen degradation and mineralization efficiencies up to an optimal value. Complete degradation of the drug and 44% mineralization were achieved under optimal conditions (2.0 bar and 100 mA). On the other hand, the results pointed out that the use of a Ti4O7 rod as counter electrode (anode) had an important contribution to the mineralization of the acetaminophen’s solutions owing to the formation of hydroxyl radicals (OH) on its surface, which highlighted the oxidative power of this anode material. The oxidation mechanisms involved during the process were assessed by electrochemical measurements with both electrodes (carbon membrane and Ti4O7 rod), and a degradation pathway for paracetamol oxidation was proposed based on the identification of the main aromatic and aliphatic degradation by-products. This DCF-EF process is presented as a potential alternative for water treatment and reuse in which the integration of membrane and electrochemical technologies brings together separation science and advanced oxidation

Procesos de Oxidación avanzada en el tratamiento de agua

A lo largo de este libro diversos autores especializados exponen el tema permitiendo al lector encontrar desde principios básicos, hasta aplicaciones de procesos, resultando ser una fuente de consulta con una visión amplia de los procesos de oxidación avanzada y sus aplicaciones dentro del tratamiento de agua.El agua es un líquido vital, sin ella no podemos subsistir. Además de usarla en nuestro hogar, se utiliza en gran variedad de procesos industriales para la transformación de materias primas en productos terminados. El agua usada industrialmente cambia su composición fisicoquímica, ya que agregamos un sinfín de compuestos orgánicos e inorgánicos. Por ello, es necesario desarrollar nuevas metodologías que permitan de manera segura y eficiente recuperar la calidad del agua usada originalmente para poder usarla.Universidad Autónoma del Estado de Méxic

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Etudes du devenir de médicaments en milieu aqueux : synthèse, caractérisation et détection des produits de transformation biotique et abiotique par les procédés d’oxydation avancée et les bioconversions

The present project contributes with valuable data for a better fundamental understanding on the fate of pharmaceutical residues in the environment, dealing with the main challenges concerning this increasingly worrying environmental issue. The used Electrochemical Advanced Oxidation Processes (EAOPs), electro-Fenton (EF) and anodic oxidation (AO), showed to be a very efficient alternative for the mineralization of acid solutions of the pharmaceuticals RNTD and FRSM, attaining almost complete mineralization of the drugs after 6h of electrolysis. A comparative study on the mineralization of RNTD solutions by EF and SPEF processes in a 2.5 L capacity pre-pilot flow plant demonstrates the higher oxidation capacity of SPEF, achieving very good mineralization rates, thus evidencing the potentiality of this technology at greater scale for the treatment of wastewaters containing pharmaceutical products. The application of an EF pre-treatment coupled with a biological process for the degradation of both drugs was conducted. EF pre-pretreatment was capable of enhancing the solution biodegradability envisaging a biological treatment, which efficiently removed the short-chain carboxylic acids that had been formerly generated during the pre-applied electrolysis. In this way, the combination of both processes was confirmed as a very promising technology for the treatment of pharmaceuticals-containing wastewater. Several transformation products (TPs) were detected and identified during the electrochemical oxidation of the studied drugs. Toxicity tests based on the bioluminescence of the marine bacteria V. fischeri. evidenced the toxicity some of these oxidation by-products, since the toxicity of the solution increased on the first stages of the electrolysis. However, the abatement of the toxicity in the final stages of the electrochemical treatments, demonstrated the effectiveness of these technologies for both the mineralization and detoxification of the RNTD and FRSM solutions. The use of the fungi Cunninghanella echinulate for the bioconversion of FRSM led to the formation of three main bio-transofrmation products: the previously identified saluamide and pyridinium, and the new detected keto-alcohol derivate. These TPs were generated by both, biological and electrochemical approches, evidencing their high probability to be found in environmental compartments as the most likely TPs of FRSM by different oxidation conditions. This study is thus presented as a very useful alternative for the assessment of the fate of pharmaceutical residues in the environmentLa pollution des eaux superficielles et souterraines par des composés organiques est bien connue comme une préoccupation majeure de l'environnement dans de nombreux pays. Si les polluants prioritaires sont actuellement surveillés par la directive cadre européenne sur l'eau, il est désormais urgent de prendre en considération les nouveaux polluants dérivés de principes actifs des produits pharmaceutiques et d'identifier leurs produits de transformation à risque. Ce travail de thèse propose une étude globale sur l'état et l'avenir des produis pharmaceutiques dans l'environnement, sur l'exemple de deux pharmaceutiques choisis, dans le cadre de cette importante problématique environnementale. Nous avons donc appliqué les procédés électrochimiques d'oxydation avancée, électro-Fenton (EF), oxydation anodique(OA) et photoélectro-Fenton solaire (PEFS), ainsi que le couplage électro-Fenton/traitement biologique pour une élimination effective des polluants médicamenteux furosémide et ranitidine. Les résultats obtenus confirment l'efficacité de ces technologies électrochimiques pour la minéralisation quasi-totale des produits pharmaceutiques étudiés. En outre, l'utilisation du pré-traitement par EF suivi d'un procédé biologique confirme la capacité de l'EF de transformer les polluants organiques en produits biodégradables qui peuvent être consommés par des microorganismes lors d'un traitement biologique, démontrant ainsi l'applicabilité potentiel de cette technique combinée, en termes d'une consommation énergétique réduite. L'identification des produits de transformation (PTs) des pharmaceutiques étudiés par voie électrochimique (électro-oxydation) et biologique (bioconversion) a été effectuée par différentes techniques d'analyse physico-chimiques. La biotransformation du FRSM a conduit à la formation de trois PT principales; saluamide, pyridinium et un dérivé céto-alcool. Les deux premiers ont aussi été détectés lors du traitement électrochimique, ce qui suggère la probabilité de les trouver dans l'environnement comme les produits de transformation les plus plausibles par des différentes conditions de dégradation. Les tests de toxicité basés sur l'inhibition de la bioluminescence des bactéries marines Vibrio fischeri ont montré que certains PT formés lors de traitement électrochimiques sont plus toxique que la molécule mère, car une augmentation de la toxicité globale de la solution a été observée au début des électrolyses. Néanmoins, la toxicité de la solution est complètement éliminée à la fin des traitements électrochimiques, ce qui indique l'efficacité de ces technologies aussi pour la détoxification des solutions des médicaments traités. Par conséquent, cette étude constitue une contribution importante à l'évaluation des risques environnementaux des produits pharmaceutique

Electro-oxidation of Ranitidine by Electrochemical Advanced Oxidation Processes.

International audienc

Etude de la dégradation de la Furosèmide par les procédés électrochimiques d’oxydation avancée

International audienc

A coupled Bio-EF process for mineralization of the pharmaceuticals furosemide and ranitidine: Feasibility assessment

International audienceA coupled Bio-EF treatment has been applied as a reliable process for the degradation of the pharmaceuticals furosemide (FRSM) and ranitidine (RNTD) in aqueous medium, in order to reduce the high energy consumption related to electrochemical technology. In the first stage of this study, electrochemical degradation of the drugs was assessed by the electro-Fenton process (EF) using a BDD/carbon-felt cell. Biodegradability of the drugs solutions was enhanced reaching BOD5/COD ratios close to the biodegradability threshold of 0.4, evidencing the formation of bio-compatible by-products (mainly short-chain carboxylic acids) which are suitable for biological post-treatment. Moreover, toxicity evaluation by the Microtox® method revealed that EF pre-treatment was able of detoxifying both, FRSM and RNTD solutions, constituting another indicator of biodegradability of EF treated solutions. In the second stage, electrolyzed solutions were treated by means of an aerobic biological process. A significant part of the short-chain carboxylic acids formed during the electrochemical phase was satisfactorily removed by the used selected microorganisms. The results obtained demonstrate the efficiency and feasibility of the integrated Bio-EF process

Electrochemical treatment of highly concentrated wastewater: a review of experimental and modeling approaches from lab- to full- scale

10.1080/10643389.2020.1820428Critical Reviews in Environmental Science and Technology522240-30

Bio- electro-Fenton: A New Combined Process. Principles and Applications.

International audienc